2020 - 2021年实体瘤药物更新
2020-2021 Drug Updates in Solid Tumors.
作者信息
Cambareri Christine
机构信息
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
出版信息
J Adv Pract Oncol. 2022 Apr;13(3):275-281. doi: 10.6004/jadpro.2022.13.3.19. Epub 2022 May 23.
Abstract
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.
摘要
在2021年JADPRO现场虚拟会议期间，药学博士、BCPS、BCOP、CSP克里斯汀·坎巴雷里向高级从业者介绍了2020年末至2021年末获批用于治疗实体瘤的药物和生物制剂，包括它们的不良事件概况。更多口服剂型的趋势以及大量获批的检查点抑制剂表明该领域的治疗模式正在发生变化。
相似文献
1
2020-2021 Drug Updates in Solid Tumors.2020 - 2021年实体瘤药物更新
J Adv Pract Oncol. 2022 Apr;13(3):275-281. doi: 10.6004/jadpro.2022.13.3.19. Epub 2022 May 23.
2
2021-2022 Drug Updates in Solid Tumors.2021 - 2022年实体瘤药物更新
J Adv Pract Oncol. 2023 Apr;14(3):227-231. doi: 10.6004/jadpro.2023.14.3.9. Epub 2023 Apr 1.
3
2020-2021 Drug Updates in Hematologic Malignancies.2020 - 2021年血液系统恶性肿瘤的药物更新
J Adv Pract Oncol. 2022 Apr;13(3):282-285. doi: 10.6004/Jadpro.2022.13.3.20. Epub 2022 May 23.
4
2022-2023 Drug Updates in Solid Tumors.2022 - 2023年实体瘤药物更新
J Adv Pract Oncol. 2024 Apr;15(3):170-176. doi: 10.6004/jadpro.2024.15.3.3. Epub 2024 Apr 1.
5
2019-2020 Drug Updates in Solid Tumors.2019 - 2020年实体瘤药物更新
J Adv Pract Oncol. 2021 Apr;12(3):275-278. doi: 10.6004/jadpro.2021.12.3.11. Epub 2021 Apr 1.
6
2020-2021 Drug Updates: Investigational Therapeutics in the Pipeline.2020 - 2021年药物更新：正在研发的研究性疗法
J Adv Pract Oncol. 2022 Apr;13(3):286-291. doi: 10.6004/jadpro.2022.13.3.21. Epub 2022 May 23.
7
2019-2020 Drug Updates in Hematologic Malignancies.2019 - 2020年血液系统恶性肿瘤的药物更新
J Adv Pract Oncol. 2021 Apr;12(3):279-283. doi: 10.6004/jadpro.2021.12.3.12. Epub 2021 Apr 1.
8
2021-2022 Drug Updates: Investigational Therapeutics in the Pipeline.2021 - 2022药物更新：正在研发中的研究性疗法
J Adv Pract Oncol. 2023 Apr;14(3):237-240. doi: 10.6004/jadpro.2023.14.3.11. Epub 2023 Apr 1.
9
2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline.2022 - 2023药物更新：正在研发中的试验性疗法
J Adv Pract Oncol. 2024 Apr;15(3):182-185. doi: 10.6004/jadpro.2024.15.3.5. Epub 2024 Apr 1.
10
2022-2023 Drug Updates in Hematologic Malignancies.2022 - 2023年血液系统恶性肿瘤的药物更新
J Adv Pract Oncol. 2024 Apr;15(3):177-181. doi: 10.6004/jadpro.2024.15.3.4. Epub 2024 Apr 1.
本文引用的文献
1
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
2
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.阿美替尼治疗 EGFR 外显子 20 插入突变型非小细胞肺癌：CHRYSALIS Ⅰ期研究的初步结果。
J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.
3
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.普拉替尼治疗晚期或转移性 RET 改变型甲状腺癌（ARROW）患者的多队列、开放标签、注册、1/2 期研究。
Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9.
4
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
5
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
6
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.TROPHY-U-01 研究：在铂类化疗和检查点抑制剂治疗后进展的转移性尿路上皮癌患者中 sacituzumab govitecan 的 II 期开放标签研究。
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
7
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
8
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.纳武利尤单抗辅助治疗食管或胃食管结合部癌。
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
9
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
10
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
Zotero 插件